United Therapeutics/$UTHR

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About United Therapeutics

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Ticker

$UTHR
Sector
Primary listing

Employees

1,305

UTHR Metrics

BasicAdvanced
$18B
15.27
$25.63
0.53
-

What the Analysts think about UTHR

Analyst ratings (Buy, Hold, Sell) for United Therapeutics stock.

Bulls say / Bears say

United Therapeutics shares soared over 42% in premarket trading after its late-stage TETON-2 trial of nebulized Tyvaso in idiopathic pulmonary fibrosis achieved its primary endpoint, improving forced vital capacity by 95.6 mL versus placebo over 52 weeks (Reuters).
In Q2 2025, United Therapeutics posted record revenue of $798.6 million—up 12% year-over-year—with Tyvaso DPI sales reaching $315.2 million (+22%). Its Board approved a $1 billion share repurchase program, showing robust financial performance and prudent capital allocation (Reuters via Tiger Brokers) (Reuters).
The FDA approved United Therapeutics’ IND for its UKidney program in January 2025, allowing a first-in-human trial of gene-edited pig kidneys. The initial cohort will enroll six patients and could expand to 50, representing a major milestone toward commercial xenotransplantation (SEC Filing)
Revenue for Q2 2025 of $798.6 million narrowly missed consensus forecasts of $804.98 million, highlighting sensitivity to market expectations despite record sales (Reuters).
United Therapeutics faces approaching generic competition as Liquidia’s Yutrepia could secure final approval once United’s Tyvaso DPI exclusivity expires in 2025, putting its core treprostinil franchise at risk (Reuters).
Xenotransplantation trials for pig kidney transplants present significant zoonotic infection risks, creating regulatory and safety challenges that could delay United Therapeutics’ organ manufacturing efforts (AFP via France24)
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2025.

UTHR Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

UTHR Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $UTHR

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs